Visit our Regulatory Affairs dedicated page
Learn how PQE Group ensures a seamless and compliant transition to the new QMSR framework.
The ICH M14 guideline, introduces a much-needed unified regulatory approach for non-interventional studies, addressing long‑standing gaps created by the absence of globally harmonized standards. Before its adoption in 2025, regulators in different regions relied on their own guidance for real‑world data–based non‑interventional studies, often resulting in inconsistencies and duplicated effort
ICHM14 Relevance and Application
As the first globally harmonized framework outlining how non-interventional safety studies should be designed, conducted, and reported, ICH M14 introduces a new approach.
Instead of starting with available data, studies must begin with a clearly defined research question. Under ICH M14, there is no one-size-fits-all approach to data. Rather, the guideline requires sponsors to think rigorously and assess whether the data at hand truly answer the defined question. The concept of “fit for purpose” moves beyond theory to a concrete regulatory expectation.
To demonstrate that data are fit for use, organizations must show that they are both relevant and reliable. In addition to accuracy, data must be traceable, complete, and representative of the target population in order to minimize distortion.
The use of real-world data in the industry is already underway and influencing regulatory decisions. With this in mind, it is clear that ICH M14 is not intended to legitimize the use of such data, but to establish a clear pathway for life sciences companies to justify their study designs from the outset. For sponsors, this means having a structured framework to demonstrate the robustness of their methodological choices from start to finish.
Rather than assuming that large databases are credible and fit for use simply because they are accessible, the guideline requires sponsors to conduct a two-phase assessment. This involves first identifying suitable candidate data sources and then carrying out a detailed verification process. By requiring thorough evaluations at the beginning, ICH M14 helps prevent delays that could arise from having to address methodological weaknesses at later, more critical stages of a study.
Beyond data considerations, ICH M14 introduces a structured approach to identifying and addressing bias. From the outset, it requires critical evaluation of potential issues at the study design stage rather than after results are generated. Through this approach, the framework aims to improve regulatory alignment and strengthen post-marketing safety monitoring, thereby enhancing public trust through greater transparency.
Once implemented, both companies and regulators are expected to benefit from more efficient reviews and clearer decision-making. For patients, this means safety monitoring grounded in rigorous, comparable evidence rather than a fragmented set of country-specific expectations.
This is particularly important for identifying risks such as selection bias and information bias, which can affect data quality from the outset. To ensure that data meet industry standards and that methodologies are robust, sponsors must plan in advance how to mitigate these risks and assess their potential impact.
The Role of GCP Experts Under ICH M14 and the Future of Real-World Evidence
This level of methodological discipline naturally extends to the expertise required to conduct such studies.
Instead of waiting until the final stages to engage GCP and methodological experts, sponsors should involve them at the concept stage, when safety questions are first being defined, to avoid potential regulatory hurdles.
ICH M14 promotes an iterative design process that begins with the research question and feasibility considerations rather than the dataset. Bringing experts in early helps ensure that all elements, from study design and bias control to documentation standards, are aligned with regulatory expectations from the outset instead of being corrected later.
This quality-by-design approach, which embeds compliance into the structure of the study itself, positions M14 as a key guideline for shaping the future of real-world evidence by transforming it into a more disciplined and harmonized regulatory tool.
Iplementing ICH M14 requires a shift in operational strategy. Sponsors must involve regulatory, methodological and data specialists early in planning, document and justify methodological choices throughout the study lifecycle, and adopt a quality‑by‑design mindset that embeds scientific rigor from the beginning.
Taken together, these practices streamline regulatory review, reduce rework and enhance the credibility of evidence packages submitted globally.
Outstanding Questions and Areas Requiring Clarity
As with any new regulatory framework, some elements of ICH M14 still require further clarification and some aspects are still open to interpretation.
-
How much validation and documentation is enough to demonstrate “fit for purpose”?
While the guideline is clear, the concept of “fit for use” still lacks defined parameters regarding the amount of validation and documentation considered sufficient. Without clearer expectations, sponsors may struggle to determine the level of evidence that will satisfy regulators and inspectors. -
How detailed should the feasibility assessment be?
The two phase feasibility assessment introduces uncertainty about the required depth and format of documentation, since these elements are not explicitly described in the guideline. More specific guidance would help ensure consistent interpretation and allow sponsors to align their internal processes with greater confidence.
Conclusion
ICH M14 marks an important step in the evolution of regulatory expectations for non-interventional studies. By promoting a question driven approach, emphasizing fit forpurpose data, and requiring proactive bias management, the guideline moves realworld evidence toward a more consistent, transparent, and globally harmonized standard.
For sponsors, adherence to M14 calls for early collaboration, stronger data governance, and a quality by design mindset. When applied successfully, this framework supports the development of more reliable evidence, facilitates regulatory review, and reinforces trust in the real-world data used to ensure patient safety.
